For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 6,995 | 13,587* | 9,730 | 7,248 |
| General and administrative expenses | 4,718 | 3,914* | 4,604 | 4,677 |
| Total operating expenses | 11,713 | 17,500 | 14,334 | 11,925 |
| Loss from operations | -11,713 | -17,500* | -14,334 | -11,925 |
| Interest income and other, net | 1,063 | 1,404 | 1,426 | 1,539 |
| Total other income | 1,063 | 1,404* | 1,426 | 1,539 |
| Net loss | -10,650 | -16,097* | -12,908 | -10,386 |
| Net unrealized gain (loss) on marketable securities | -112 | -104* | 41 | -45 |
| Total comprehensive loss | -10,762 | -16,201 | -12,867 | -10,431 |
| Basic EPS | -0.33 | -0.5 | -0.4 | -0.32 |
| Diluted EPS | -0.33 | -0.5 | -0.4 | -0.32 |
| Basic Average Shares | 32,559,704 | 32,376,316 | 32,464,893 | 32,195,366 |
| Diluted Average Shares | 32,559,704 | 32,376,316 | 32,464,893 | 32,195,366 |
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)